Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...

BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling ...

SHINE's new large-scale medical isotope production facility. Submitted photo. Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in Milwaukee and ...

@2024 - All Right Reserved.

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...

The MarketWatch News Department was not involved in the creation of this content. Lutetium-177 (Lu-177) Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, ...

Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177 Lu) Companies enter into an additional manufacturing and supply agreement for ...

TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations. This is an ASCO Meeting Abstract from the ...

Lutetium-177 vipivotide tetraxetan 1 is a widely approved breakthrough drug for metastatic prostate cancer. It is manufactured and distributed by Novartis (Basel, Switzerland) under the trade name ...

Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic ...

GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as ...